Efficacy of rituximab as a single-agent therapy for the treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in patients with Common Variable Immunodeficiency (CVID)

Publication date: Available online 5 November 2018

Source: The Journal of Allergy and Clinical Immunology: In Practice

Author(s): Lorenzo Cereser, Riccardo De Carli, Rossano Girometti, Alessandro De Pellegrin, Federico Reccardini, Barbara Frossi, Marco De Carli

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2DpmJ4W